Inspire Medical Systems (INSP Quick QuoteINSP - Free Report) reported $204.58 million in revenue for the quarter ended March 2026, representing a year-over-year increase of 1.6%. EPS of $0.10 for the same period compares to $0.10 a year ago.

The reported revenue compares to the Zacks Consensus Estimate of $198.74 million, representing a surprise of +2.94%. The company delivered an EPS surprise of +127.62%, with the consensus EPS estimate being -$0.36.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Inspire performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Total U.S. sales territories: 284 compared to the 301 average estimate based on two analysts.
• Geographic Revenue- All other countries: $8.98 million compared to the $9.65 million average estimate based on three analysts. The reported number represents a change of +16.5% year over year.
• Geographic Revenue- United States: $195.6 million compared to the $191.73 million average estimate based on three analysts. The reported number represents a change of +1% year over year.

View all Key Company Metrics for Inspire here>>>

Shares of Inspire have returned +3.1% over the past month versus the Zacks S&P 500 composite's +10% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.